pharmaphorum1y
AZ first to AKT finish line, but FDA clears narrow label
The company’s head of oncology, Dave Fredrickson, said the approval of Truqap “reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need to test ...